Ligand Pharmaceuticals Incorporated (LGND) : Thursdays money flow data in Ligand Pharmaceuticals Incorporated (LGND) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $0.81 million, whereas, $0.5 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.63, in favor of the bulls. The total money flow into the stock was $0.31 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $0 million. The total value of block trades done on upticks was $0 million. Ligand Pharmaceuticals Incorporated (LGND) fell $0.44 and traded at $123.31, down -0.36% for the day, over previous days close. On a weekly basis, the shares are 0.97% over the previous weeks close.
Ligand Pharmaceuticals Incorporated (LGND) stock is expected to deviate a maximum of $19.68 from the average target price of $134.4 for the short term period. 5 Street Experts have initiated coverage on the stock with the most promising target being $150 and the most muted being $104. The stock has recorded a 20-day Moving Average of 6.27% and the 50-Day Moving Average is 4.46%.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND): The stock opened at $124.78 on Thursday but the bulls could not build on the opening and the stock topped out at $124.82 for the day. The stock traded down to $121.05 during the day, due to lack of any buying support eventually closed down at $123.73 with a loss of -0.02% for the day. The stock had closed at $123.75 on the previous day. The total traded volume was 286,511 shares.
Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Companys technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimers disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.